Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma.

fear of cancer recurrence frustration health care survey qualitative study renal cell carcinoma

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2019
Historique:
received: 03 08 2018
accepted: 03 01 2019
entrez: 7 2 2019
pubmed: 7 2 2019
medline: 7 2 2019
Statut: epublish

Résumé

Despite numerous therapeutic advances in renal cell carcinoma (RCC), little is known about patients' perspectives on cancer care. An international survey was conducted to identify points of frustration associated with cancer care reported by patients with RCC. Data were obtained from an online survey, conducted from April 1 to June 15, 2017, through social media and patient networking platforms. This survey obtained baseline demographic, clinicopathologic, and treatment-related information. Open-ended questions accessed sources of frustration in cancer-related care and patients' suggestions for amelioration. Responses were categorized and reviewed by independent reviewers. A qualitative analysis was performed and the Kruskal-Wallis test was used to define associations between baseline characteristics and sources of frustration. Among 450 patients surveyed, 71.5% reported sources of frustration, classified as either emotional (48.4%) or practical (23.1%). The most common were fear of recurrence/progression (15.8%), distrust of their cancer care system (12.9%), and lack of appropriate information (9.8%). Female gender and non-clear cell histology were associated with both types of frustration, and older age was linked to practical sources of frustration. Patients suggested solutions included greater compassion among health care practitioners (20.7%), better access to information (15.1%) and research to improve their chances of being cured (14.7%). Sources of frustration related to emotional and practical causes were identified amongst patients with RCC. Certain demographic and clinical characteristics were associated with more sources of frustration. This study provides the first characterization of specific ways to improve the patient experience by addressing common frustrations.

Identifiants

pubmed: 30723705
doi: 10.3389/fonc.2019.00011
pmc: PMC6349746
doi:

Types de publication

Journal Article

Langues

eng

Pagination

11

Références

N Engl J Med. 2003 Jul 31;349(5):427-34
pubmed: 12890841
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
Lancet. 2008 Aug 9;372(9637):449-56
pubmed: 18653228
J Natl Compr Canc Netw. 2009 Jun;7(6):659-65
pubmed: 19555587
Front Oncol. 2015 Apr 08;5:67
pubmed: 25905038
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Psychooncology. 2016 Jul;25(7):772-8
pubmed: 26464337
Health Psychol. 2016 Dec;35(12):1329-1333
pubmed: 27175578
N Engl J Med. 2016 Dec 8;375(23):2246-2254
pubmed: 27718781
Can Urol Assoc J. 2016 Nov-Dec;10(11-12Suppl7):S242-S244
pubmed: 28096936
J Clin Oncol. 2017 Sep 10;35(26):2993-3001
pubmed: 28644771
Eur Urol. 2017 Dec 7;:null
pubmed: 29223605
J Glob Oncol. 2018 Sep;(4):1-8
pubmed: 29281478

Auteurs

Cristiane Decat Bergerot (CD)

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.

Dena Battle (D)

Kidney Cancer Research Alliance (KCCure), Alexandria, VA, United States.

Paulo Gustavo Bergerot (PG)

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.

Nazli Dizman (N)

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.

Eric Jonasch (E)

University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Hans J Hammers (HJ)

University of Texas Southwestern Medical Cancer Center, Dallas, TX, United States.

Daniel J George (DJ)

Duke University Medical Center, Duke Cancer Institute, Durham, NC, United States.

Axel Bex (A)

Division of Surgical Oncology, Department of Urology, Netherlands Cancer Center, Amsterdam, Netherlands.

Borje Ljungberg (B)

Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.

Sumanta Kumar Pal (SK)

Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.

Michael D Staehler (MD)

Department of Urology, Ludwig-Maximilians University, Munich, Germany.

Classifications MeSH